<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35746899</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1789</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neuropathology : official journal of the Japanese Society of Neuropathology</Title><ISOAbbreviation>Neuropathology</ISOAbbreviation></Journal><ArticleTitle>A pathologically confirmed case of combined amyotrophic lateral sclerosis with C9orf72 mutation and multiple system atrophy.</ArticleTitle><Pagination><StartPage>302</StartPage><EndPage>308</EndPage><MedlinePgn>302-308</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/neup.12808</ELocationID><Abstract><AbstractText>Hexanucleotide repeat expansions in C9orf72 account for a large proportion of cases of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration. There have been occasional reported cases associated with this expansion but also additional extrapyramidal clinical features. However, only very rarely has there been pathological confirmation of a parkinsonian syndrome associated with a C9orf72 repeat expansion. To date, as far as we are aware, there have been no reported pathologically confirmed cases of ALS with C9orf72 mutation and multiple system atrophy (MSA). We report a case of a man who initially presented with extrapyramidal features, including cogwheel rigidity, and, therefore, was clinically considered likely to have Parkinson's disease or a parkinsonian syndrome. Subsequent examination six months later revealed additional abnormal upper and lower motor neuron signs, raising the strong possibility of ALS. He had a rapid clinical decline and died 16&#x2009;months after the first presentation. It was noted that his father also had ALS, and that his mother had a parkinsonian syndrome, suggestive of progressive supranuclear palsy. The macroscopic and microscopic examination of the brain and spinal cord revealed ALS pathology with neuronal loss, especially of the anterior horns of the cord and the motor cortex. This was associated with numerous neuronal cytoplasmic inclusions immunoreactive for phosphorylated transactivation response DNA-binding protein of 43 Da (TDP43). There were additional pathological features, including p62-immunoreactive cerebellar neuronal cytoplasmic inclusions, fully in keeping with a C9orf72 repeat expansion, and this was confirmed on molecular analysis. However, there was also &#x3b1;-synuclein pathology in the form of oligodendroglial cytoplasmic inclusions in the basal ganglia, cerebellum, and brainstem, indicative of MSA. To our knowledge, this is the first reported case of pathologically confirmed combined ALS-C9orf72 and MSA.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Neuropathology published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>King</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7974-2589</Identifier><AffiliationInfo><Affiliation>Department Of Clinical Neuropathology, King's College Hospital, Denmark Hill, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>London Neurodegenerative Diseases Brain Bank and Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yuan Kai</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Eastbourne District General Hospital, King's Drive, East Sussex, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Shalmai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>London Neurodegenerative Diseases Brain Bank and Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troakes</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>London Neurodegenerative Diseases Brain Bank and Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Neuropathology</MedlineTA><NlmUniqueID>9606526</NlmUniqueID><ISSNLinking>0919-6544</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019578" MajorTopicYN="Y">Multiple System Atrophy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="Y">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">multiple system atrophy</Keyword><Keyword MajorTopicYN="N">parkinsonian</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>2</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35746899</ArticleId><ArticleId IdType="pmc">PMC9541494</ArticleId><ArticleId IdType="doi">10.1111/neup.12808</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus&#x2010;Hernandez M, Mackenzie IR, Boeve BF et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p&#x2010;linked frontotemporal dementia and amyotrophic lateral sclerosis. Neuron 2011; 72: 245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21&#x2010;linked ALS&#x2010;FTD. Neuron 2011; 72: 257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesage S, Le Ber I, Condroyer C et al. C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain 2013; 136: 385&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3984141</ArticleId><ArticleId IdType="pubmed">23413259</ArticleId></ArticleIdList></Reference><Reference><Citation>Schottlaender LV, Polke JM, Ling H et al. The analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism. Neurobiol Aging 2015; 36: 1221.e1&#x2013;1221.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4321829</ArticleId><ArticleId IdType="pubmed">25308964</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Sarraj S, King A, Troakes C et al. p62 positive, TDP&#x2010;43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72&#x2010;linked FTLD and MND/ALS. Acta Neuropathol 2011; 122: 691&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">22101323</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Chen Y, Wei Q et al. C9ORF72 repeat expansions in Chinese patients with Parkinson's disease and multiple system atrophy. J Neural Transm (Vienna) 2016; 123: 1341&#x2013;1345.</Citation><ArticleIdList><ArticleId IdType="pubmed">27473499</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholz SW, Majounie E, Revesz T et al. Multiple system atrophy is not caused by C9orf72 hexanucleotide repeat expansions. Neurobiol Aging 2015; 36: e1221&#x2013;e1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4315721</ArticleId><ArticleId IdType="pubmed">25281017</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JS, Quinzii C, Dunning&#x2010;Broadbent J et al. Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72. JAMA Neurol 2014; 71: 771&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4051831</ArticleId><ArticleId IdType="pubmed">24733620</ArticleId></ArticleIdList></Reference><Reference><Citation>Schottlaender LV, Holton JL, Houlden H. Multiple system atrophy and repeat expansions in C9orf72. JAMA Neurol 2014; 71: 1190&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">25200542</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JS, Kuo SH. Multiple system atrophy and repeat expansions in C9orf72&#x2010;&#x2010;reply. JAMA Neurol 2014; 71: 1191&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4211280</ArticleId><ArticleId IdType="pubmed">25200544</ArticleId></ArticleIdList></Reference><Reference><Citation>Federoff M, Schottlaender LV, Houlden H, Singleton A. Multiple system atrophy: The application of genetics in understanding etiology. Clin Auton Res 2015; 25: 19&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5217460</ArticleId><ArticleId IdType="pubmed">25687905</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xfc;llner U, Abele M, Schmitz&#x2010;Huebsch T et al. Probable multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry 2004; 75: 924&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739076</ArticleId><ArticleId IdType="pubmed">15146018</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara K, Momose Y, Tokiguchi S et al. Multiplex families with multiple system atrophy. Arch Neurol 2007; 64: 545&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420317</ArticleId></ArticleIdList></Reference><Reference><Citation>Sailer A, Scholz SW, Nalls MA et al. A genome&#x2010;wide association study in multiple system atrophy. Neurology 2016; 87: 1591&#x2013;1598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5067544</ArticleId><ArticleId IdType="pubmed">27629089</ArticleId></ArticleIdList></Reference><Reference><Citation>King A, Al&#x2010;Sarraj S, Troakes C et al. Mixed tau, TDP&#x2010;43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant. Acta Neuropathol 2013; 125: 303&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">23053136</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniek KF, Murray ME, Rutherford NJ et al. Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathol 2013; 125: 289&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551994</ArticleId><ArticleId IdType="pubmed">23053135</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson AC, Thompson JC, Weedon L et al. No interaction between tau and TDP&#x2010;43 pathologies in either frontotemporal lobar degeneration or motor neurone disease. Neuropathol Appl Neurobiol 2014; 40: 844&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">24861427</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>